Dice Thinks It Holds An Ace With Oral IL-17 Inhibitor In Psoriasis
The company believes it has a potential best-in-class oral drug for psoriasis in development following positive first-in-human clinical trial data. A larger Phase II study is needed.
The company believes it has a potential best-in-class oral drug for psoriasis in development following positive first-in-human clinical trial data. A larger Phase II study is needed.